PMID- 35096888
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220201
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy.
PG  - 799427
LID - 10.3389/fmed.2021.799427 [doi]
LID - 799427
AB  - Background: No study explores the effectiveness of adalimumab in 
      sight-threatening Vogt-Koyanagi-Harada (VKH) patients in China. Objective: To 
      evaluate the short-term effectiveness and safety of adalimumab (ADA) in patients 
      with sight-threatening Vogt-Koyanagi-Harada (VKH) disease refractory to 
      conventional therapy. Methods: Medical records of VKH patients who had been 
      treated with systemic glucocorticoids and immunosuppressants but whose condition 
      was poorly controlled were collected and analyzed. Primary outcomes comprised of 
      best-corrected visual acuity (BCVA), intraocular inflammation, relapses, and 
      glucocorticoid-sparing effects. Other outcomes included central macular thickness 
      (CMT), intraocular manifestations and adverse events (AEs). Results: Nine 
      refractory VKH patients with a median age of 30 (16, 43) years old were enrolled 
      in this study and received treatment for a median of 10 (7, 11) months. Mean BCVA 
      improved from LogMar 0.63 +/- 0.50 (20/72 or 0.36 +/- 0.26 in Snellen chart) at 
      baseline to LogMar 0.50 +/- 0.37 (20/82 or 0.41 +/- 0.28 in Snellen chart) at final 
      visit (P = 0.090). The anterior chamber cell grade decreased from 2 (1.75, 3)+ at 
      baseline to 0.5 (0, 1.25)+ cell at final visit (P < 0.001). The vitritis grade 
      decreased from 1 (1, 1) + cell at baseline to 0 (0, 1)+ cell at final visit (P < 
      0.001). Patients suffered a median of 1 (0, 2) relapse during treatment. CMT 
      remained stable from 238.50 +/- 144.94 mum at baseline to 219.28 +/- 77.20 mum at final 
      visit (P = 0.553). The mean prednisone dosage decreased from 21.91 +/- 18.39 mg/d 
      to 2.73 +/- 4.10 mg/d (P = 0.005). No severe AEs were found during treatment. 
      Conclusions: The outcomes indicated that ADA was an effective and safe option for 
      VKH patients refractory to conventional therapy by controlling inflammation, 
      preserving visual function and reducing the daily glucocorticoid dose.
CI  - Copyright (c) 2022 Yang, Tao, Huang, Liu, Li, Xie, Wen, Chi and Su.
FAU - Yang, Shizhao
AU  - Yang S
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Tao, Tianyu
AU  - Tao T
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Huang, Zhaohao
AU  - Huang Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Liu, Xiuxing
AU  - Liu X
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Li, He
AU  - Li H
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Xie, Lihui
AU  - Xie L
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Wen, Feng
AU  - Wen F
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, 
      China.
FAU - Chi, Wei
AU  - Chi W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, 
      China.
FAU - Su, Wenru
AU  - Su W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220112
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8789678
OTO - NOTNLM
OT  - TNF-alpha inhibitor
OT  - Vogt-Koyanagi-Harada (VKH)
OT  - adalimumab
OT  - refractory
OT  - treatment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/01 06:00
MHDA- 2022/02/01 06:01
PMCR- 2022/01/12
CRDT- 2022/01/31 06:00
PHST- 2021/10/21 00:00 [received]
PHST- 2021/12/20 00:00 [accepted]
PHST- 2022/01/31 06:00 [entrez]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/02/01 06:01 [medline]
PHST- 2022/01/12 00:00 [pmc-release]
AID - 10.3389/fmed.2021.799427 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Jan 12;8:799427. doi: 10.3389/fmed.2021.799427. 
      eCollection 2021.